secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001157523-23-001294
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q2 revenue up 8.9% to $1.06B; GAAP EPS $1.89, non-GAAP $2.69; guidance narrowed upward
--------------------------------------------------------------------------------

- Revenue $1.06B (+8.9% YoY, organic +11.2%); DSA segment revenue $663.5M (+12.1%) drove growth.
- GAAP net income $97.0M (−11.3%), diluted EPS $1.89; non-GAAP EPS $2.69 (−2.9%).
- RMS segment revenue $209.9M (+12.6%, organic +13.9%) driven by China model shipments; Manufacturing segment revenue $186.5M (−4.2%).
- FY 2023 guidance narrowed: organic revenue growth 5.5%–7.5% (prior 5.0%–7.5%); non-GAAP EPS $10.30–$10.90 (prior $9.90–$10.90).
- CEO cites cautious biopharma spending but confidence in differentiated scientific breadth and DSA backlog.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/0001157523-23-001294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/a53513759.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer